Imagine living with a cancer that has returned or spread after you have already tried the best standard treatments. For patients with recurrent or metastatic squamous cell carcinoma of the head and neck, options are often very limited. This study looked at a new medicine called becotatug vedotin given to 67 people who had already progressed on platinum-based chemotherapy and immune checkpoint inhibitors. These are powerful drugs that stop cancer cells from hiding, but they do not work for everyone.
The main goal was to see if the drug could shrink tumors. About 21% of patients achieved an objective response, meaning their tumors got smaller enough to measure. On average, those who responded saw their tumors stay smaller for nearly 11 months. However, the average time before the cancer started growing again was about 2.9 months, and the average total time lived after starting treatment was 6.7 months.
Safety was a major concern because these patients are already fragile. Most people, 91% of them, experienced side effects. The most common issues included skin rashes, intense itching, constipation, and low red blood cell counts. Despite these side effects, the team described the safety profile as manageable. This early trial suggests the drug might be a future option, but more research is needed to confirm these findings before it becomes a standard choice.
